The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Laboratory Medicine · 2025
DOI: 10.1093/labmed/lmae080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, 2025. Verfasst von Christian J Puzo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT, US. Hauptthemen laut MEDLINE: Cyclams, Benzylamines, Hematopoietic Stem Cell Mobilization, Blood Component Removal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Mobilisation
Abstract (Originalsprache)
Objective
The aim of this study was to determine the efficacy of plerixafor for hematopoietic stem cell (HSC) mobilization prior to autologous stem cell transplantation (aSCT) for patients with multiple myeloma (MM) and various lymphomas, using an oncologist-guided HSC collection goal and markers of cell viability.
Methods
A retrospective chart review of all aSCT patients at Yale New Haven Hospital between 2017 and 2021 who met diagnostic criteria for MM, non-Hodgkin, or Hodgkin lymphoma (n = 382) was undertaken. Logistic regression evaluated plerixafor’s effect on meeting the individual’s HSC goal. The use of t-tests determined plerixafor’s relationship to HSC yield and analysis of variance testing assessed its effect on cell viability.
Results
Mobilization with granulocyte colony–stimulating factor (G-CSF) and plerixafor (odds ratio [OR] = 0.08; P < .05) relative to G-CSF alone was negatively associated with meeting the individual’s HSC goal. Diffuse large B-cell lymphoma in patients mobilized with plerixafor yielded fewer HSCs than those without plerixafor (t = –2.78; P = .03). Mobilization regimen (P = .13) had no association with HSC viability. Mobilization failure with plerixafor was rare but occurred in patients with multiple risk factors, including exposure to several rounds of HSC-affecting chemotherapy.
Conclusion
Plerixafor is effective across multiple diagnoses using an oncologist-driven HSC collection endpoint. Its association with mobilization failure is likely attributable to its use in patients predicted to be poor mobilizers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, CT, US.
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US.
- Department of Pathology, Yale School of Medicine, New Haven, CT, US.
ORCID-Profile: Alexa J Siddon
Zitieren
APA
Puzo, C. J., Li, P., Tormey, C. A., & Siddon, A. J. (2025). The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Laboratory Medicine. https://doi.org/10.1093/labmed/lmae080
Vancouver
Puzo CJ, Li P, Tormey CA, Siddon AJ. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Laboratory Medicine. 2025. doi:10.1093/labmed/lmae080
BibTeX
@article{Puzo2025,
author = {Puzo, Christian J and Li, Philippa and Tormey, Christopher A and Siddon, Alexa J},
title = {The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges},
journal = {Laboratory Medicine},
year = {2025},
doi = {10.1093/labmed/lmae080}
}
EUVIMED